Navigation Links
Endo Pharmaceuticals Announces Proposal to Change Name of Parent Company and Rebrands Enterprise: Revealing an Innovative Corporate Structure Dedicated to Redefining Healthcare Value
Date:3/1/2012

CHADDS FORD, Pa., March 1, 2012 /PRNewswire/ -- Endo (Nasdaq: ENDP), a diversified healthcare solutions company, today announced the aggregation of its operating companies as part of an enterprise-wide branding initiative.  The integration of its diversified operating companies and the introduction of its new corporate identity reflect the company's significant transformation as a result of a series of recent strategic acquisitions and business development decisions.

In connection with this initiative, Endo Pharmaceuticals Holdings Inc., the parent company, will ask its shareholders to approve changing its name to Endo Health Solutions Inc. at its annual meeting of shareholders in May 2012.

With a uniquely diversified foundation of complementary healthcare businesses within well-defined therapeutic areas, the new Endo is structured to provide integrated, end-to-end solutions in pain management and urology. The vision is to approach therapeutic areas and disease states as pathways, and to identify, develop and incorporate medical interventions beyond the traditional chemical and biological treatments.

The company will deliver various products and services through its four operating companies: AMS, a developer of innovative medical devices; Endo Pharmaceuticals, a provider of branded pharmaceuticals; HealthTronics, a provider of medical services, practice management software, laboratory solutions and EHR technology; and Qualitest, a manufacturer of high-quality generic pharmaceuticals.

"With the right organizations in place, we have modernized our four distinct operating companies into one enterprise that reflects a powerful combination of compatible organizations aimed at delivering fully integrated healthcare solutions for the benefit of physicians, payers and patients," said Dave Holveck, President and CEO of Endo.  "We are excited to
'/>"/>

SOURCE Endo Pharmaceuticals Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Orthopedic Soft ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html About Orthopedic ... the mass of cells that connect, support, or ... soft tissues such as tendons, ligaments, cartilage, fascia, ...
(Date:8/27/2014)... 2014 Decision Resources Group finds that the ... Memphis health system and hospital sector in ... rivals Methodist Le Bonheur Healthcare and Baptist Memorial Health ... patient care. In addition, a national contract recently signed ... plan enrollment in the Memphis ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Heart ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart ... in the human heart which control the flow ... affected with heart valve diseases such as valvular ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Memphis-area Health Systems Turn Attention to Clinical Integration 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
(Date:8/28/2014)... MMAR Medical is pleased to announce their ... regular customers to enjoy several perks and benefits when ... wholesale license. It’s a great choice for independent athletes, ... who regularly purchase medical braces but could use a ... active lifestyle or those of your club, group or ...
(Date:8/28/2014)... The need for larger space has become more ... The new location - 4700 Bryant Irvin Court, Fort Worth, ... space than TLC had in the past, as well as ... our new location because it represents a good fit for ... in size compared to the current one, the building itself ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Aeroflow ... to acquire as part of a strategic expansion ... is positioned for taking ownership of new businesses ... increase economies of scale. , Last week, the ... with Hometown Respiratory to increase service in the ...
(Date:8/27/2014)... 2014 According to a new market ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 DiaSorin has ... Utility of 1,25 Dihydroxyvitamin D,” will feature guest speaker ... Penny George Institute for Health and Healing Integrative Medicine. ... the Penny George Institute for Health and Healing and ... Health Care, Minneapolis, Minnesota. He also serves as a ...
Breaking Medicine News(10 mins):Health News:MMAR Medical Announces Customer Membership Program 2Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3
... gives new meaning to the word transformative, researchers from ... are integrating some of the best practices of industry ... propel the development of innovative cancer treatments from the ... Cancer Center has initiated the Translational Research Acceleration Collaboration ...
... Foundation for a,Healthy Florida, the philanthropic affiliate of ... approved $951,486 in grants to be awarded this,winter ... needs in their communities., "The Blue Foundation ... to quality health-related services for Floridians who are ...
... lives could be,saved over the next five years through ... the 30 hardest hit countries in,Africa, according to a ... rapid scale-up would increase annual economic output,by as much ... cases, and,free up 427,000 needed hospital beds over five ...
... MIAMI, Jan. 25 OPKO Health, Inc. (Amex: ... and Richard C.,Pfenniger, Jr. to its Board of Directors. ... David Eichler. Mr. Pfenniger was,appointed to fill the vacancy ... a newly created Board position., "The addition of ...
... Calif., Jan. 25 IPC The,Hospitalist Company, Inc. (Nasdaq: ... yesterday the initial public offering of 5,200,000,shares of its ... $16.00 per share.,The Company has agreed to sell 3,300,000 ... to sell the remaining 1,900,000 shares of,common stock. The ...
... as 30,000 deaths each year, study says , , FRIDAY, ... greatly reduce their risk of developing ovarian cancer, and the ... study confirms. , The use of oral contraceptives has long ... The authors of the new study say their findings show ...
Cached Medicine News:Health News:ITRAC on track and bridging gap between academic research and applied discovery 2Health News:ITRAC on track and bridging gap between academic research and applied discovery 3Health News:Eleven Florida Nonprofit Organizations to Receive Grants Totaling Nearly $1 Million From The Blue Foundation 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 4Health News:OPKO Health Announces Changes to Board of Directors 2Health News:OPKO Health Announces Changes to Board of Directors 3Health News:IPC The Hospitalist Company, Inc. Prices Initial Public Offering 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 3
... on Smart Cards. Insert the card and turn ... turns itself off after the programmed time. The ... of treatments. Simply provide your patient with the ... progress on the next visit.,The initial set of ...
... battery operated dual-channel therapy system designed for use ... 4 Conti also includes a programme for treating ... 4 Conti provokes a contraction of the pelvic ... muscles need exercising. In URGE incontinence, ELPHA 4 ...
... disposable template is designed for ... eliminate the need for cleaning. ... premium silicone molded over a ... needle placement while maintaining needle ...
... is designed for use with the ... prostate brachytherapy. Please be sure that ... the graphics on the Reusable Template. ... from lower surface which fits into ...
Medicine Products: